Scholar Rock Holding (SRRK) Operating Expenses (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Operating Expenses of $102.0 million in Q1 2026, up 11.01% quarter-over-quarter from $91.9 million in Q4 2025, and up 32.33% on a YoY basis from $77.1 million in Q1 2025.
Scholar Rock Holding (SRRK) Operating Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Operating Expenses history runs 10 years deep, the most recent figure standing at $102.0 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 32.33% year-over-year to $102.0 million; the TTM figure through Mar 2026 stood at $409.6 million (up 51.29% YoY), while the FY2025 annual figure was $384.6 million, up 52.6% from the prior year.
- Operating Expenses was $102.0 million for Q1 2026 at Scholar Rock Holding, up from $91.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $112.1 million in Q2 2025 to a low of $39.1 million in Q2 2023.
- Historically, Operating Expenses has averaged $63.4 million across 5 years, with a median of $58.4 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses dropped 9.42% in 2023, then surged 88.42% in 2025.
- A 5-year view of Operating Expenses shows it stood at $40.4 million in 2022, then advanced by 18.81% to $48.0 million in 2023, then surged by 44.4% to $69.4 million in 2024, then surged by 32.5% to $91.9 million in 2025, then climbed by 11.01% to $102.0 million in 2026.
- The last three Operating Expenses figures came in at $102.0 million (Q1 2026), $91.9 million (Q4 2025), and $103.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 4.33 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 32.68 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -138.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 15.76 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 574,669.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.85 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -67.40 Mn |
| 10 | Scholar Rock Holding | 5.57 Bn | 5.09 Bn | - | 102.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.02 Mn |
| Dec 31, 2025 | 91.90 Mn |
| Sep 30, 2025 | 103.55 Mn |
| Jun 30, 2025 | 112.11 Mn |
| Mar 31, 2025 | 77.09 Mn |
| Dec 31, 2024 | 69.36 Mn |
| Sep 30, 2024 | 64.78 Mn |
| Jun 30, 2024 | 59.50 Mn |
| Mar 31, 2024 | 58.42 Mn |
| Dec 31, 2023 | 48.03 Mn |
| Sep 30, 2023 | 43.67 Mn |
| Jun 30, 2023 | 39.08 Mn |
| Mar 31, 2023 | 40.51 Mn |
| Dec 31, 2022 | 40.43 Mn |
| Sep 30, 2022 | 43.86 Mn |
| Jun 30, 2022 | 43.15 Mn |
| Mar 31, 2022 | 40.13 Mn |
| Dec 31, 2021 | 39.41 Mn |
| Sep 30, 2021 | 42.54 Mn |
| Jun 30, 2021 | 34.87 Mn |